Publications by authors named "F Aguilo Lucia"

Multidrug-resistant is a significant healthcare challenge that particularly affects vulnerable patients through opportunistic nosocomial infections. Surveillance is crucial for monitoring the prevalence of these infections. Eighty-four KPC strains (2019-2022) were collected from patients admitted in Fondazione Policlinico Universitario Campus Bio-Medico.

View Article and Find Full Text PDF

The treatment landscape for Rheumatoid Arthritis (RA) has evolved significantly with the introduction of Janus kinase inhibitors (JAKi), such as Tofacitinib (TOFA), which offer a new therapeutic option for patients who have failed or are intolerant to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Safety concerns, particularly related to cardiovascular and cancer risks, prompted a need for additional investigation in real-world clinical settings. This study aimed to evaluate the long-term effectiveness and predictors of response to TOFA in two subpopulations of RA patients, categorized by differing cardiovascular risk profiles.

View Article and Find Full Text PDF

Due to the recent advances in the systemic treatment of non-small cell lung cancer, the management of locoregional recurrences, especially after initial radiotherapy (with or without concurrent chemotherapy), is of increasing significance. The potential alternatives in this setting include: a salvage local strategy (based on surgery, radiotherapy or thermoablative treatment), promising approach, but sometimes difficult to implement in often frail patients, and whose modalities remain under-researched; or alternatively, the initiation of systemic treatment, where the prognosis aligns with that of de novo metastatic patients. This comprehensive literature review focused on salvage radiotherapy treatment of recurrent non-small cell lung carcinomas, after initial radiotherapy, with or without associated systemic treatment.

View Article and Find Full Text PDF
Article Synopsis
  • Radiotherapy plays a crucial role in treating cancer but often struggles with effective local control, especially in advanced tumours that are resistant to radiation.
  • Surrounding healthy tissues often limit how much radiation can be safely used, which can lead to complications.
  • New agents like chemotherapies and targeted monoclonal antibodies have shown promise in improving treatment outcomes, and current research is exploring innovative radioenhancers, particularly nanoparticles like NBTXR3 and AGuIX®.
View Article and Find Full Text PDF